OOIR: Observatory of International Research

Papers

(The median citation count of Blood Reviews is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Not all LGL leukemias are created equal	99
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	69
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	67
Editorial Board	65
Radiation and leukaemia: Which leukaemias and what doses?	63
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	63
Clinical burden of hemophilia in older adults: Beyond bleeding risk	62
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	62
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	60
Advances in the critical care management for patients with hematological malignancies	59
Artificial intelligence in sickle disease	58
Thalassaemia in China	54
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	52
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	46
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	46
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	46
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	45
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	44
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	42
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	42
Chasing leukemia differentiation through induction therapy, relapse and transplantation	42
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	41
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	38
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game	38
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	37

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	37
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	35
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	34
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	31
Endothelial cells: major players in acute myeloid leukaemia	31
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	31
CHIPing away the progression potential of CHIP: A new reality in the making	30
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	30
Preservation of fertility in female patients with hematologic diseases	29
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	29
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review	28
Down syndrome and leukemia: An insight into the disease biology and current treatment options	27
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	27
Current challenges in conditioning regimens for MDS transplantation	26
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies	26
Current state and next-generation CAR-T cells in multiple myeloma	25
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	25
Complementary and alternative medicine for children with sickle cell disease: A systematic review	25
Richter's transformation: Transforming the clinical landscape	25
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	25
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	24
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	24
Beyond the blood: A practical guide to thalassemia care in the emergency department	24
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists	24
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	23
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	23
The mythological chimera and new era of relapse prediction post-transplant	23
Optimizing high dose melphalan	21
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	21
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	21
Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms	21
Αlpha-thalassemia: A practical overview	21
Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity	21
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	20
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	20
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	20
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	19
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	19
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	19
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	19
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	19
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	19
Innovations in red blood cell preservation	19
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	18
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	18
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	18
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	18
The use of bone-modifying agents in multiple myeloma	17
The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators	17
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies	17

Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia	17
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	17
The microbiome-lymphoma Axis: A systematic review and Meta-analysis of gut Dysbiosis pattern in diffuse large B-cell lymphoma	16
Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases	16
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	16
The gut microbiome in B cell lymphoma	16
The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?	15
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS	15
Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies	15
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B	15
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review	15
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2	15
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review	14
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol	13
Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China	13
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly	13
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme	13
Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research	13
Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research	13
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	13
Primary cutaneous T-cell lymphoma (Mycosis fungoides and Sézary syndrome): A practical compartment-based review	13
Dysbiosis and immunothrombosis – How platelets and the gut microbiome interact	13
Editorial Board	13
Evans syndrome revisited	12
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	12
Disparity in hematological malignancies: From patients to health care professionals	12
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	12
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	12
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	12
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	12
Chronic myeloid leukaemia: Biology and therapy	12
Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody	12
Unmet needs in hemophilic arthropathy	12
Editorial Board	11
Editorial Board	11
Platelet transfusion guidelines for thrombocytopenic patients in non-surgical and non-traumatic care settings: A systematic review and methodological quality assessment	10
The development of post-transplant cyclophosphamide: Half a century of translational team science	10
Autologous stem cell transplantation in AL amyloidosis: Muddy waters	10
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond	10
Follicular lymphoma: The long and winding road leading to your cure?	10
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches	10
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment	10
Editorial Board	9
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era	9
BCL-2 inhibition in haematological malignancies: Clinical application and complications	9
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review	9
Continuing progress in radioimmunotherapy for hematologic malignancies	9
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	9
CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access	9
Dismantling relapsed/refractory mantle cell lymphoma	9
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?	9
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH	9
Could (should) we abandon total body irradiation for conditioning in children with leukemia	9
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies	8
Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]	8
From MGUS to multiple myeloma: Unraveling the unknown of precursor states	8
Acupuncture in hematologic malignancies and hematopoietic cell transplantation	8
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	8
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances	8
Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma	8
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies	8
Editorial Board	8
Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies	8
Reinventing the wheel in ischemic stroke: Novel aspects in ADAMTS13 and von Willebrand axis	7
Navigating the perils and pitfalls throughout the consent process in hematopoietic cell transplantation	7
Editorial Board	7
Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight	7
An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety	7
Does PTCY increase the risk of infections?	7
Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives	7
Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis	7
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management	7
Editorial Board	7
Programmed death inhibitors in CNS B-cell lymphoma: A literature review	7
Prognostic performance of machine learning in predicting haematological cancer outcomes: systematic review and meta-analysis	7
DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management	7
CLL update 2022: A continuing evolution in care	7
Aiming for the cure in myeloma: Putting our best foot forward	7
PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance	7